A Phase 1 interventional study of pregabalin and naproxen sodium in Acute Pain, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
We are interested in whether bunionectomy can be used as a model to study the treatment of acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS) medications (such as ibuprofen) and other pain relieving drugs. We are interested to know if this model is useful to study other drugs for the treatment of acute pain. The other drugs being tested in this study are pregabalin and naproxen sodium. These drugs are approved for use by the Food and Drug Administration (FDA). This study is designed to test whether these two drugs are effective in treating pain after a bunionectomy.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
This study's enrollment of 100 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Browse Acute Pain studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin
Drug: naproxen sodium
Drug: Comparator: Placebo
Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
Also known as: naproxen
Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery
Total dose (amount) of hydromorphone via patient controlled analgesic (PCA) pump required in the 24 hours post-surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.
Time frame: First 24 hours following surgery
Time to First Request of PCA Hydromorphone
Time (in hours) to first patient controlled analgesic (PCA) pump use after surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.
Time frame: First 24 hours following surgery
First Patient Entered: 25 July 2007 Last Patient Last Visit: 28 January 2008 1 site
| Milestone | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo |
|---|---|---|---|
| Started | 36 | 34 | 30 |
| Completed | 32 | 29 | 28 |
| Not completed | 4 | 5 | 2 |
| Withdrew: Dosing error | 1 | 0 | 0 |
| Withdrew: Incomplete data | 0 | 2 | 0 |
| Withdrew: Protocol violation | 3 | 2 | 1 |
| Withdrew: Early termination | 0 | 1 | 1 |
Total dose (amount) of hydromorphone via patient controlled analgesic (PCA) pump required in the 24 hours post-surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.
| milligrams | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo |
|---|---|---|---|
| Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery | 2.94 (2.00 to 5.35) | 2.07 (0.80 to 4.60) | 5.96 (4.50 to 7.70) |
Time (in hours) to first patient controlled analgesic (PCA) pump use after surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.
| Hours | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo |
|---|---|---|---|
| Time to First Request of PCA Hydromorphone | 7.3 (5.8 to 9.4) | 9.1 (7.1 to 13.6) | 5.8 (5.1 to 7.4) |
Collected over AEs were collected from the time the subject signed consent until 14 days following the last dose of study mediciation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 300 mg | — | 0/36 (0%) | 26/36 (72.2%) |
| Naproxen Sodium 550 mg | — | 0/34 (0%) | 19/34 (55.9%) |
| Placebo | — | 0/30 (0%) | 25/30 (83.3%) |
| Event | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 16/36 | 14/34 | 21/30 |
| VomitingGastrointestinal disorders | 7/36 | 9/34 | 18/30 |
| HeadacheNervous system disorders | 8/36 | 1/34 | 4/30 |
| DizzinessNervous system disorders | 6/36 | 5/34 | 3/30 |
| PruritusSkin and subcutaneous tissue disorders | 1/36 | 5/34 | 5/30 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/36 | 1/34 | 4/30 |
| Oxygen Saturation DecreasedInvestigations | 2/36 | 0/34 | 3/30 |
| Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders | 0/36 | 0/34 | 2/30 |
| ConstipationGastrointestinal disorders | 2/36 | 2/34 | 1/30 |
| PainGeneral disorders | 0/36 | 2/34 | 0/30 |
| Age, Continuous(years) | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 40.3 ± 14.1 | 40.6 ± 13.5 | 38.8 ± 11.6 | 39.9 ± 13.1 |
| Sex: Female, Male(Participants) | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 27 | 23 | 23 | 73 |
| Male | 5 | 6 | 5 | 16 |
| Body Weight(Kilograms) | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 72.3 ± 18.1 | 76.7 ± 17.2 | 77.2 ± 16.9 | 75.3 ± 17.4 |
| Lidocaine Use(Milliliters) | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 15.0 ± 2.3 | 15.9 ± 2.7 | 14.6 ± 1.6 | 15.2 ± 2.2 |
| Propofol Use(Milligrams) | Pregabalin 300 mg | Naproxen Sodium 550 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 348.4 ± 132.9 | 364.5 ± 122.8 | 353.9 ± 105.8 | 355.4 ± 121.1 |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Naproxen